Australia's A$200 million pledge to fight the A$14.7 billion Alzheimer's economic cost

16 February 2017

The economic cost of dementia to Australia has been revealed in a new report which highlights the pressing need for greater research.

In the Alzheimer’s Australia report, it is estimated that dementia will cost A$14.7 billion ($11.3 billion) to the country in 2017, and a 5% reduction in the incidence of the condition would save A$5.7 billion.

As he welcomed the release of the report, Australia’s Minister for Aged Care, Ken Wyatt, said the government had committed A$200 million over five years to dementia research, an area where there have been some expensive failures in drug development globally.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK